The treatment of alopecia is limited by a lack of therapies that induce and sustain disease remission. Given the negative psychosocial impact of hair loss, patients that do not see significant hair restoration with conventional therapies often turn to complementary and alternative medicine (CAM). Although there are a variety of CAM treatment options on the market for alopecia, only a few are backed by multiple randomized controlled trials. Further, these modalities are not regulated by the Food and Drug Administration and there is a lack of standardization of bioactive in gredients in over-the-counter vitamins, herbs, and supplements. In this article, we provide a comprehensive review of the efficacy, safety, and tolerability of CAM, including natural products and mind and body practices, in the treatment of hair loss. Overall, there is a need for additional studies investigating CAM for alopecia with more robust clinical design and standardized, quantitative outcomes.

Keywords:
Alopecia, Complementary and alternative medicine, Efficacy
1.
National Center for Complementary and Integrative Health: Complementary, Alternative, or Integrative Health: What’s in a Name? 2016. https://nccih.nih.gov/sites/nccam.nih.gov/files/Whats_In_A_Name_06-16-2016.pdf (accessed January 1, 2018).
2.
National Center for Complementary and Integrative Health: National Health Interview Survey 2012. 2014. https://nccih.nih.gov/research/statistics/NHIS/2012 (accessed January 28, 2018].
3.
Fuhrmann T, Smith N, Tausk F: Use of complementary and alternative medicine among adults with skin disease: updated results from a national survey. J Am Acad Dermatol 2010; 63: 1000–1005.
4.
Faghri S, Tamura D, Kraemer KH, DiGiovanna JJ: Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations. J Med Genet 2008; 45: 609–621.
5.
Sacharow SJ, Picker JD, Levy HL: Homocystinuria caused by cystathionine beta-synthase deficiency; in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al. (eds): GeneReviews®. Seattle, University of Washington, 2017. http://www.ncbi.nlm.nih.gov/books/NBK1524/ (accessed July 4, 2018).
6.
Neil MW: The absorption of cystine and cysteine from rat small intestine. Biochem J 1959; 71: 118–124.
8.
Camfield DA: Nutritional-based nutraceuticals in the treatment of anxiety; in: Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders. Cham, Springer, 2017, pp 81–101.
9.
Hertel H, Gollnick H, Matthies C, Baumann I, Orfanos CE: Low dosage retinol and L-cystine combination improve alopecia of the diffuse type following long-term oral administration (in German). Hautarzt 1989; 40: 490–495.
10.
Morganti P, Fabrizi P, James B, Bruno C: Effect of gelatin-cystine and Serenoa repens extract on free radicals level and hair growth. J Appl Cosmetol 1998; 16: 57–64.
11.
Gehring W, Gloor M: Use of the phototrichogram to assess the stimulation of hair growth – an in vitro study of women with androgenetic alopecia. Z Hautkr 2000; 75: 419–423.
12.
Lengg N, Heidecker B, Seifert B, Trüeb: Dietary supplement increases anagen hair rate in women with telogen effluvium: results of a double-blind, placebo-controlled trial. Therapy 2007; 4: 59–65.
13.
Rushton DH, Norris MJ, Dover R, Busuttil N: Causes of hair loss and the developments in hair rejuvenation. Int J Cosmet Sci 2002; 24: 17–23.
14.
Wood JM, Decker H, Hartmann H, Chavan B, Rokos H, Spencer JD, et al: Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J 2009; 23: 2065–2075.
15.
Oshimura E: Effects of arginine on hair damage via oxidative coloring process (abstract). Europe PMC, 2004. http://europepmc.org/abstract/med/15645092 (accessed June 27, 2018).
16.
Fischer TW, Hipler UC, Elsner P: Effect of caffeine and testosterone on the proliferation of human hair follicles in vitro. Int J Dermatol 2007; 46: 27–35.
17.
Fischer TW, Herczeg-Lisztes E, Funk W, Zillikens D, Bíró T, Paus R: Differential effects of caffeine on hair shaft elongation, matrix and outer root sheath keratinocyte proliferation, and transforming growth factor-β2/insulin-like growth factor-1-mediated regulation of the hair cycle in male and female human hair follicles in vitro. Br J Dermatol 2014; 171: 1031–1043.
18.
Sisto T, Bussoletti C, Celleno L: Efficacy of a cosmetic caffeine shampoo in androgenetic alopecia management. J Appl Cosmetol 2012; 31: 57–66.
19.
Bussoletti C, Mastropietro F, Tolani M: Use of a caffeine shampoo for the treatment of male androgenetic alopecia. J Appl Cosmetol 2011; 29: 167–180.
20.
Bussoletti C, Tolaini MV, Celleno L: Efficacy of a cosmetic phyto-caffeine shampoo in female androgenetic alopecia. G Ital Dermatol Venereol 2018, DOI: 10.23736/S0392-0488.18.05499-8.
21.
Bussoletti C, Mastropietro F, Tolaini M, Celleno L: Use of a cosmetic caffeine lotion in the treatment of male androgenetic alopecia. J Appl Cosmetol 2011; 29: 167–180.
22.
Dhurat R, Chitallia J, May TW, Jayaraaman AM, Madhukara J, Anandan S, et al: An open-label randomized multicenter study assessing the noninferiority of a caffeine-based topical liquid 0.2% versus minoxidil 5% solution in male androgenetic alopecia. Skin Pharmacol Physiol 2017; 30: 298–305.
23.
Golpour M, Rabbani H, Farzin D, Azizi F: Comparing the effectiveness of local solution of minoxidil and caffeine 2.5% with local solution of minoxidil 2.5% in treatment of androgenetic alopecia. J Mazandaran Univ Med Sci 2013; 23: 30–36.
24.
Pazoki-Toroudi H: The efficacy and safety of minoxidil 5% combination with azelaic acid 1/5% and caffeine 1% solution on male pattern hair loss (abstract). J Invest Dermatol 2013; 133:S84.
25.
Dressler C, Blumeyer A, Rosumeck S, Arayesh A, Nast A: Efficacy of topical caffeine in male androgenetic alopecia. J Dtsch Dermatol Ges 2017; 15: 734–741.
26.
Harada N, Okajima K, Arai M, Kurihara H, Nakagata N: Administration of capsaicin and isoflavone promotes hair growth by increasing insulin-like growth factor-I production in mice and in humans with alopecia. Growth Horm IGF Res 2007; 17: 408–415.
27.
Hordinsky M, Ericson M: Autoimmunity: alopecia areata. J Investig Dermatol Symp Proc 2004; 9: 73–78.
28.
Yilmaz G: Capsaicin Bats .500. Spec Rep, 2002. http://dermatologytimes.modernmedicine.com/dermatology-times/news/clinical/dermatology/capsaicin-bats-500 (accessed January 29, 2018].
29.
Ehsani A, Toosi S, Seirafi H, Akhyani M, Hosseini M, Azadi R, et al: Capsaicin vs. clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol 2009; 23: 1451–1453.
30.
Harada N, Okajima K, Narimatsu N, Kurihara H, Nakagata N: Effect of topical application of raspberry ketone on dermal production of insulin-like growth factor-I in mice and on hair growth and skin elasticity in humans. Growth Horm IGF Res 2008; 18: 335–344.
31.
Fadus MC, Lau C, Bikhchandani J, Lynch HT: Curcumin: an age-old anti-inflammatory and anti-neoplastic agent. J Tradit Complement Med 2017; 7: 339–346.
32.
Pumthong G, Asawanonda P, Varothai S, Jariyasethavong V, Triwongwaranat D, Suthipinittharm P, et al: Curcuma aeruginosa, a novel botanically derived 5α-reductase inhibitor in the treatment of male-pattern baldness: a multicenter, randomized, double-blind, placebo-controlled study. J Dermatol Treat 2012; 23: 385–392.
33.
Srivilai J, Waranuch N, Tangsumranjit A, Khorana N, Ingkaninan K: Germacrone and sesquiterpene-enriched extracts from Curcuma aeruginosa Roxb. increase skin penetration of minoxidil, a hair growth promoter. Drug Deliv Transl Res 2018; 8: 140–149.
34.
Arreola R, Quintero-Fabián S, López-Roa RI, Flores-Gutiérrez EO, Reyes-Grajeda JP, Carrera-Quintanar L, et al: Immunomodulation and anti-inflammatory effects of garlic compounds. J Immunol Res 2015; 2015: 401630.
35.
Hajheydari Z, Jamshidi M, Akbari J, Mohammadpour R: Combination of topical garlic gel and betamethasone valerate cream in the treatment of localized alopecia areata: a double-blind randomized controlled study. Indian J Dermatol Venereol Leprol 2007; 73: 29.
36.
Lassus A, Eskelinen E: A comparative study of a new food supplement, Viviscal®, with fish extract for the treatment of hereditary androgenic alopecia in young males. J Int Med Res 1992; 20: 445–453.
37.
Lassus A, Santalahti J: Treatment of alopecia areata and alopecia totalis with Viviscal. J Int Med Res 1992; 445–453.
38.
Ablon G, Dayan S: A randomized, double-blind, placebo-controlled, multi-center, extension trial evaluating the efficacy of a new oral supplement in women with self-perceived thinning hair. J Clin Aesthet Dermatol 2015; 8: 15–21.
39.
Hornfeldt C, Holland M, Bucay VW, Roberts WE, Waldorf HA, Dayan SH: The safety and efficacy of a sustainable marine extract for the treatment of thinning hair: a summary of new clinical research and results from a panel discussion on the problem of thinning hair and current treatments. J Drugs Dermatol 2015; 14:s15–22.
40.
Lassus A, Santalahti J, Sellmann M: Treatment of hereditary androgenic alopecia in middle aged males by combined oral and topical administration of special marine extract-compound (Viviscal) for 8 months. Nouv Dermatol Anglo Fr Int Dermatol 1994; 13: 254–255.
41.
Majass M, Puuste O, Prästbacka B, Brorsdotter-Johansson P: Treatment of alopecia areata, alopecia totalis and alopecia universalis with oral Viviscal for 12 months. Swedish Association for Alopecia, 1996. http://www.llogo.hu/viviscal/study4.html (accessed December 9, 2017).
42.
Pereira J: Treatment of androgenetic alopecia with a marine-based extract of proteins and polysaccharides. Rev Bras Med 1997; 54: 144–149.
43.
Thom E: Efficacy and tolerability of Hairgain® in individuals with hair loss: a placebo-controlled, double-blind study. J Int Med Res 2001; 29: 2–6.
44.
Stephens & Associates, Inc: A pilot consumer research study to evaluate the overall acceptability of a Viviscal supplement in females with self perceived thinning hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles. Viviscal Prof Clin Trials Conduct Res, 2010. https://www.viviscalprofessional.com/media/ClinicalTrialsBooklet_LR.pdf.
45.
Jackson B: A 4-month study evaluating the efficacy and tolerability of an oral supplement for the treatment of thinning hair in African American women. Viviscal Prof Clin Trials Conduct Res, 2011. https://www.viviscalprofessional.com/media/ClinicalTrialsBooklet_LR.pdf
46.
Ablon G: A double-blind, placebo-controlled study evaluating the efficacy of an oral supplement in women with self-perceived thinning hair. J Clin Aesthetic Dermatol 2012; 5: 28–34.
47.
Stephens & Associates, Inc: A 6-month clinical trial to determine, whether Viviscal® dietary/food supplement containing marine proteins shows statistically-significant benefi ts in reducing hair shedding and increasing hair diameter in females with sub-clinical hair thinning/loss. 2013. https://www.viviscalprofessional.com/media/ClinicalTrialsBooklet_LR.pdf.
48.
Bloch L: Demonstrating the efficacy of a nutraceutical for promoting hair growth using a digital photography technique with posterior image analysis; 2015 World Hair Congress, Miami.
49.
Ablon G: A 3-month, randomized, double-blind, placebo-controlled study evaluating the ability of an extra-strength marine protein supplement to promote hair growth and decrease shedding in women with self-perceived thinning hair. Dermatol Res Pract 2015; 2015: 841570.
50.
Rizer RL, Stephens TJ, Herndon JH, Sperber BR, Murphy J, Ablon GR: A marine protein-based dietary supplement for subclinical hair thinning/loss: results of a multisite, double-blind, placebo-controlled clinical trial. Int J Trichology 2015; 7: 156–166.
51.
Ablon G: A 6-month, randomized, double-blind, placebo-controlled study evaluating the ability of a marine complex supplement to promote hair growth in men with thinning hair. J Cosmet Dermatol 2016; 15: 358–366.
52.
Fischer TW, Slominski A, Tobin DJ, Paus R: Melatonin and the hair follicle. J Pineal Res 2008; 44: 1–15.
53.
Fischer TW, Burmeister G, Schmidt HW, Elsner P: Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. Br J Dermatol 2004; 150: 341–345.
54.
Fischer TW, Trüeb RM, Hänggi G, Innocenti M, Elsner P: Topical melatonin for treatment of androgenetic alopecia. Int J Trichology 2012; 4: 236–245.
55.
Sharquie KE, Al-Obaidi HK: Onion juice (Allium cepa L.), a new topical treatment for alopecia areata. J Dermatol 2002; 29: 343–346.
56.
Kamimura A, Takahashi T, Watanabe Y: Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair growing agent. Phytomedicine 2000; 7: 529–536.
57.
Takahashi T, Kamiya T, Yokoo Y, Hasegawa A: Procyanidin oligomers selectively and intensively promote proliferation of mouse hair epithelial cells in vitro and activate hair follicle growth in vivo. J Invest Dermatol 1999; 112: 310–316.
58.
Takahashi T, Kamimura A, Yokoo Y, Honda S, Watanabe Y: The first clinical trial of topical application of procyanidin B-2 to investigate its potential as a hair growing agent. Phytother Res 2001; 15: 331–336.
59.
Takahashi T, Kamimura A, Kagoura M, Toyoda M, Morohashi M: Investigation of the topical application of procyanidin oligomers from apples to identify their potential use as a hair-growing agent. J Cosmet Dermatol 2005; 4: 245–249.
60.
Tenore GC, Caruso D, Buonomo G, D’Avino M, Santamaria R, Irace C, et al: Annurca apple nutraceutical formulation enhances keratin expression in a human model of skin and promotes hair growth and tropism in a randomized clinical trial. J Med Food 2018; 21: 90–103.
61.
Kamimura A, Takahashi T: Procyanidin B-3, isolated from barley and identified as a hair-growth stimulant, has the potential to counteract inhibitory regulation by TGF-beta1. Exp Dermatol 2002; 11: 532–541.
62.
Kamimura A, Takahashi T, Morohashi M, Takano Y: Procyanidin oligomers counteract TGF-β1- and TGF-β2-induced apoptosis in hair epithelial cells: an insight into their mechanisms. Skin Pharmacol Physiol 2006; 19: 259–265.
63.
Carbin BE, Larsson B, Lindahl O: Treatment of benign prostatic hyperplasia with phytosterols. Br J Urol 1990; 66: 639–641.
64.
Cho YH, Lee SY, Jeong DW, Choi EJ, Kim YJ, Lee JG, et al: Effect of pumpkin seed oil on hair growth in men with androgenetic alopecia: a randomized, double-blind, placebo-controlled trial. Evid Based Complement Alternat Med 2014; 2014: 549721.
65.
Ribeiro-Santos R, Carvalho-Costa D, Cavaleiro C, Costa HS, Albuquerque TG, Castilho MC, et al: A novel insight on an ancient aromatic plant: the rosemary (Rosmarinus officinalis L.). Trends Food Sci Technol 2015; 45: 355–368.
66.
Panahi Y, Taghizadeh M, Marzony ET, Sahebkar A: Rosemary oil vs minoxidil 2% for the treatment of androgenetic alopecia: a randomized comparative trial. Skinmed 2015; 13: 15–21.
67.
Iehlé C, Délos S, Guirou O, Tate R, Raynaud JP, Martin PM: Human prostatic steroid 5 alpha-reductase isoforms – a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995; 54: 273–279.
68.
Chaterjee S, Agrawala S: Saw palmetto (Serenoa repens) in androgenic alopecia – an effective phytotherapy. Nat Prod Radiance 2003; 2: 302–305.
69.
Prager N, Bickett K, French N, Marcovici G: A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-α-reductase in the treatment of androgenetic alopecia. J Altern Complement Med 2002; 8: 143–152.
70.
Rossi A, Mari E, Scarnò M, Garelli V, Maxia C, Scali E, et al: Comparative effectiveness and finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol 2012; 25: 1167–1173.
71.
Wessagowit V, Tangjaturonrusamee C, Kootiratrakarn T, Bunnag T, Pimonrat T, Muangdang N, et al: Treatment of male androgenetic alopecia with topical products containing Serenoa repens extract. Australas J Dermatol 2016; 57:e76–e82.
72.
Zempleni J, Hassan YI, Wijeratne SS: Biotin and biotinidase deficiency. Expert Rev Endocrinol Metab 2008; 3: 715–724.
73.
Wolf B: Biotinidase deficiency; in Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mefford HC, et al. (eds): GeneReviews®. Seattle, University of Washington, 1993. http://www.ncbi.nlm.nih.gov/books/NBK1322/ (accessed December 14, 2017).
74.
Trüeb RM: Serum biotin levels in women complaining of hair loss. Int J Trichology 2016; 8: 73–77.
75.
Soleymani T, Lo Sicco K, Shapiro J: The infatuation with biotin supplementation: is there truth behind its rising popularity? A comparative analysis of clinical efficacy versus social popularity. J Drugs Dermatol 2017; 16: 496–500.
76.
Schulpis KH, Karikas GA, Tjamouranis J, Regoutas S, Tsakiris S: Low serum biotinidase activity in children with valproic acid monotherapy. Epilepsia 2001; 42: 1359–1362.
77.
Schulpis KH, Georgala S, Papakonstantinou ED, Michas T, Karikas GA: The effect of isotretinoin on biotinidase activity. Skin Pharmacol Appl Skin Physiol 1999; 12: 28–33.
78.
Patel DP, Swink SM, Castelo-Soccio L: A review of the use of biotin for hair loss. Skin Appendage Disord 2017; 3: 166–169.
79.
National Institutes of Health, Office of Dietary Supplements: Biotin. 2017. https://ods.od.nih.gov/factsheets/Biotin-HealthProfessional/ (accessed December 24, 2018).
80.
FDA: Safety Communications – The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication. https://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm586505.htm (accessed Jun 26, 2018).
81.
Endocrine News: January 2016: Thyroid Month: Beware of Biotin. 2016. https://endocrinenews.endocrine.org/january-2016-thyroid-month-beware-of-biotin/ (accessed June 26, 2018).
82.
Kummer S, Hermsen D, Distelmaier F: Biotin treatment mimicking graves’ disease. N Engl J Med 2016; 375: 704–706.
83.
Li D, Radulescu A, Shrestha RT, Root M, Karger AB, Killeen AA, et al: Association of biotin ingestion with performance of hormone and nonhormone assays in healthy adults. JAMA 2017; 318: 1150–1160.
84.
Kriegel MA, Manson JE, Costenbader KH: Does vitamin D affect risk of developing autoimmune disease?: a systematic review. Semin Arthritis Rheum 2011; 40: 512–531.e8.
85.
Xie Z, Komuves L, Yu Q-C, Elalieh H, Ng DC, Leary C, et al: Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth. J Invest Dermatol 2002; 118: 11–16.
86.
Tsai T-Y, Huang Y-C: Vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2018; 78: 207–209.
87.
Miller R, Conic RZ, Bergfeld W, Mesinkovska NA: Prevalence of comorbid conditions and sun-induced skin cancers in patients with alopecia areata. J Investig Dermatol Symp Proc 2015; 17: 61–62.
88.
Berth-Jones J, Hutchinson PE: Alopecia totalis does not respond to the vitamin-D analogue calcipotriol. J Dermatol Treat 2009; 1: 293–294.
89.
Orecchia G, Rocchetti GA: Topical use of calcipotriol does not potentiate squaric acid dibutylester effectiveness in the treatment of alopecia areata. J Dermatol Treat 1995; 6: 21–23.
90.
Kim DH, Lee JW, Kim IS, Choi SY, Lim YY, Kim HM, et al: Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol 2012; 24: 341–344.
91.
Çerman AA, Solak SS, Altunay İ, Küçükünal NA: Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol 2015; 14: 616–620.
92.
Narang T, Daroach M, Kumaran MS: Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study. Dermatol Ther 2017; 30.
93.
Serbinova E, Kagan V, Han D, Packer L: Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. Free Radic Biol Med 1991; 10: 263–275.
94.
Beoy LA, Woei WJ, Hay YK: Effects of tocotrienol supplementation on hair growth in human volunteers. Trop Life Sci Res 2010; 21: 91–99.
95.
Saper R, Rash R: Zinc: an essential micronutrient. Am Fam Physician 2009; 79: 768–772.
96.
Kil MS, Kim CW, Kim SS: Analysis of serum zinc and copper concentrations in hair loss. Ann Dermatol 2013; 25: 405–409.
97.
Tenenbaum S, Opdyke DL: Antimicrobial properties of the pyrithione salts VII. In vitro methods for comparing pyrithiones to standard antimicrobials. Food Cosmet Toxicol 1969; 7: 223–232.
98.
Guéniche A, Viac J, Lizard G, Charveron M, Schmitt D: Protective effect of zinc on keratinocyte activation markers induced by interferon or nickel. Acta Derm Venereol 1995; 75: 19–23.
99.
Rostan EF, DeBuys HV, Madey DL, Pinnell SR: Evidence supporting zinc as an important antioxidant for skin. Int J Dermatol 2002; 41: 606–611.
100.
Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988; 119: 627–632.
101.
Reeder NL, Kaplan J, Xu J, Youngquist RS, Wallace J, Hu P, et al: Zinc pyrithione inhibits yeast growth through copper influx and inactivation of iron-sulfur proteins. Antimicrob Agents Chemother 2011; 55: 5753–5760.
102.
Berger RS, Fu JL, Smiles KA, Turner CB, Schnell BM, Werchowski KM, et al: The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol 2003; 149: 354–362.
103.
Siavash M, Tavakoli F, Mokhtari F: Comparing the effects of zinc sulfate, calcium pantothenate, their combination and minoxidil solution regimens on controlling hair loss in women: a randomized controlled trial. J Res Pharm Pract 2017; 6: 89.
104.
Park H, Kim CW, Kim SS, Park CW: The therapeutic effect and the changed serum zinc level after zinc supplementation in alopecia areata patients who had a low serum zinc level. Ann Dermatol 2009; 21: 142–146.
105.
Alhaj E, Alhaj N, Alhaj NE: Diffuse alopecia in a child due to dietary zinc deficiency. Skinmed 2007; 6: 199–200.
106.
Sharquie K, Noaimi A, Shwail E: Oral zinc sulphate in treatment of alopecia areata (double blind; cross-over study). J Clin Exp Dermatol Res 2012; 3: 150.
107.
US Department of Health and Human Services: NIH Fact Sheet: Mind-Body Medicine Practices in Complementary and Alternative Medicine. https://report.nih.gov/NIHfactsheets/ViewFactSheet.aspx?csid=102 (accessed January 22, 2018).
108.
National Center for Complementary and Integrative Health: Acupuncture: In Depth. 2008. https://nccih.nih.gov/health/acupuncture/introduction (accessed February 26, 2018).
109.
Tan EK, Millington GWM, Levell NJ: Acupuncture in dermatology: an historical perspective. Int J Dermatol 2009; 48: 648–652.
110.
Lee HW, Jun JH, Lee JA, Lim H-J, Lim H-S, Lee MS: Acupuncture for treating alopecia areata: a protocol of systematic review of randomised clinical trials. BMJ Open 2015; 5:e008841.
111.
Maeda T, Taniguchi M, Matsuzaki S, Shingaki K, Kanazawa S, Miyata S: Anti-inflammatory effect of electroacupuncture in the C3H/HeJ mouse model of alopecia areata. Acupunct Med 2013; 31: 117–119.
112.
Ge S: Treatment of alopecia areata with acupuncture. J Tradit Chin Med 1990; 10: 199–200.
113.
Zhu Q, Wu F: Clinical observation on acupuncture treatment of alopecia areata. J Acupunct Tuina Sci 2011; 9: 162–164.
114.
Yoon H-J: A case study of androgenetic alopecia in woman improved by pharmacopuncture therapy and needle-embedding therapy. J Korean Med Ophthalmol Otolaryngol Dermatol 2014; 27: 162–170.
115.
Hay IC, Jamieson M, Ormerod AD: Randomized trial of aromatherapy: successful treatment for alopecia areata. Arch Dermatol 1998; 134: 1349–1352.
116.
Walsh D: Using aromatherapy in the management of psoriasis. Nurs Stand 1996; 11: 53–56.
117.
Putt SC, Weinstein L, Dzindolet MT: A case study: massage, relaxation, and reward for treatment of alopecia areata. Psychol Rep 1994; 74: 1315–1318.
118.
Willemsen R, Vanderlinden J, Deconinck A, Roseeuw D: Hypnotherapeutic management of alopecia areata. J Am Acad Dermatol 2006; 55: 233–237.
119.
Harrison PV, Stepanek P: Hypnotherapy for alopecia areata. Br J Dermatol 1991; 124: 509–510.
120.
Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J: Hypnosis in refractory alopecia areata significantly improves depression, anxiety, and life quality but not hair regrowth. J Am Acad Dermatol 2010; 62: 517–518.
121.
Murphy D: Counselling Psychology: A Textbook for Study and Practice. Wiley, 2017.
122.
Teshima H, Sogawa H, Mizobe K, Kuroki N, Nakagawa T: Application of psychoimmunotherapy in patients with alopecia universalis. Psychother Psychosom 1991; 56: 235–241.
123.
Bersani FS, Minichino A, Enticott PG, Mazzarini L, Khan N, Antonacci G, et al: Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. Eur Psychiatry 2013; 28: 30–39.
124.
Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS: The Clinical TMS Society consensus review and treatment recommendations for tms therapy for major depressive disorder. Brain Stimulat 2016; 9: 336–346.
125.
Anninos P, Karpouzis A, Kotini A, Kouskoukis C: Magnetic stimulation in universalis alopecia areata: clinical and laboratory findings. WSEAS International Conference on Cellular and Molecular Biology, Athens, 2005.
126.
Anninos P, Karpouzis A, Kotini A: Magnetoencephalography measurements and exogenous magnetic stimulation in therapeutic management of universalis alopecia areata: about three cases. Gazz Med Ital 2004; 163: 281–284.
127.
Bureau JP, Ginouves P, Guilbaud J, Roux ME: Essential oils and low-intensity electromagnetic pulses in the treatment of androgen-dependent alopecia. Adv Ther 2003; 20: 220–229.
128.
Hahnemann S, Devrient CH, Stratten S: The homœopathic medical doctrine, or, “Organon of the healing art”. Dublin, W.F. Wakeman, 1833. http://archive.org/details/bub_gb_EnEFAAAAQAAJ (accessed February 27, 2018).
129.
Itamura R: Effect of homeopathic treatment of 60 Japanese patients with chronic skin disease. Complement Ther Med 2007; 15: 115–120.
130.
Shaoqiong X: Three typical dermatological cases treated by Dr. Li Yueping. J Tradit Chin Med 2005; 25: 129–131.
131.
Cash TF, Price VH, Savin RC: Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993; 29: 568–575.
132.
Otberg N, Finner AM, Shapiro J: Androgenetic alopecia. Endocrinol Metab Clin North Am 2007; 36: 379–398.
133.
Gan DC, Sinclair RD: Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc 2005; 10: 184–189.
134.
Hamada K, Randall VA: Inhibitory autocrine factors produced by the mesenchyme-derived hair follicle dermal papilla may be a key to male pattern baldness. Br J Dermatol 2006; 154: 609–618.
135.
Rogers NE, Avram MR: Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008; 59: 547–566; quiz 567–568.
136.
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N: A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011; 65: 1126–1134.e2.
137.
Messenger AG, Rundegren J: Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150: 186–194.
138.
Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G: Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010; 146: 1141–1150.
139.
Ellis JA, Sinclair R, Harrap SB: Androgenetic alopecia: pathogenesis and potential for therapy. Expert Rev Mol Med 2002; 4: 1–11.
140.
Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ: Incidence of alopecia areata in Olmsted County, Minnesota, 1975 Through 1989. Mayo Clin Proc 1995; 70: 628–633.
141.
Islam N, Leung PSC, Huntley AC, Eric Gershwin M: The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev 2015; 14: 81–89.
142.
Delamere FM, Sladden MJ, Dobbins HM, Leonardi-Bee J: Interventions for alopecia areata. Cochrane Database Syst Rev 2008; 2:CD004413.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.